Impact & 3Rs
Reducing animal use
While participating to new drug discovery approaches, patient-derived models may also impact positively our environment by reducing animal use in drug discovery.
Patient-derived models participate to implement the 3Rs principle: Replacement, Reduction and Refinement.
Our strong emphasis on human models reflects not only the imperious need to put the human patient at the forefront of drug discovery for human diseases but is also in accordance with Directive 2010/63/EU, the European Union legislation “on the protection of animals used for scientific purposes”.
At Ksilink, we strongly believe that our technology based on human models that mimic better human physiology will give way to the implementation of the 3Rs principle for the use of animals (Replacement, Reduction and Refinement) in drug discovery.
We recommend the following articles if you are interested in that matter:
- Read the article from the New York Times “Could the next blockbuster drug be lab-rat free?”
- Read about Directive 2010/63/EU
- Read the article “Targeted, Inclusive Strategies Are Needed to Enable Full Replacement of Animal Use in the European Union”
- Read the article “Replacing Animal Testing with Stem Cell-Organoids : Advantages and Limitations”